-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Initiates Coverage On Rani Therapeutics Hldgs with Buy Rating, Announces Price Target of $6

Benzinga·08/18/2026 11:53:21
語音播報
Chardan Capital analyst Andreas Argyrides initiates coverage on Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy rating and announces Price Target of $6.